Publications by authors named "Secundino Ferrer"

Claim this Profile
A
A randomized phase II study comparing consolidation with a single dose of Y ibritumomab tiuxetan maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results.
Armando López-Guillermo, Miguel Ángel Canales, Ivan Dlouhy, Santiago Mercadal, Javier Briones, Secundino Ferrer

Leuk Lymphoma· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
José A García-Marco, Javier López Jiménez, Valle Recasens, Miguel Fernández Zarzoso, Eva González-Barca, Secundino Ferrer

Haematologica· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients.
Eva González-Barca, Miguel A Canales, Antonio Salar, Secundino Ferrer, Eva Domingo-Domenech

Acta Haematol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.
Pau Abrisqueta, Neus Villamor, María José Terol, Eva González-Barca, Marcos González, Secundino Ferrer

Blood· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment.
Eva González-Barca, Miguel Canales, Montse Cortés, M Jesus Vidal, Antonio Salar, Secundino Ferrer

Nucl Med Commun· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intracardiac migration of a ventriculoperitoneal shunt.
Jordi Pérez-Bovet, Roser Garcia-Armengol, Mа Carme Joly Torta, Secundino Martín Ferrer

Can J Neurol Sci· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathologic cervical fracture in a patient with secondary hyperparathyroidism.
Diana Faur, Jordi Pérez-Bovet, Secundino Martín Ferrer, Martí Vallès Prats

Kidney Int· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab.
Carlos Vallejo, Eduardo Ríos, Javier de la Serna, Isidro Jarque, Christelle Ferrá, Secundino Ferrer

Expert Rev Hematol· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
Francesc Bosch, Pau Abrisqueta, Neus Villamor, María José Terol, Eva González-Barca, Secundino Ferrer

J Clin Oncol· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry.
Sandra Quijano, Antonio López, Juan Manuel Sancho, Carlos Panizo, Guillermo Debén, Secundino Ferrer

J Clin Oncol· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis